Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.87%
#2 Biconomy Biconomy +19.56%
#3 MiL.k Alliance MiL.k Alliance +17.80%
#4 THORChain THORChain +17.68%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +16.45%
#6 Gigachad Gigachad +16.31%
#7 Bless Bless +15.32%
#8 The Black Bull The Black Bull +14.68%
#9 MetaDAO MetaDAO +13.65%
#10 XPIN Network XPIN Network +13.17%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Hybio Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd.

300199
Classificação em ações #5173
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Preço da ação
$3.33
Valor de mercado
$2.95B
Variação (1 dia)
1.50%
Variação (1 ano)
-8.64%
País
CN
Negociar Hybio Pharmaceutical Co., Ltd. (300199)

Categoria

Healthcare
Lucros da Hybio Pharmaceutical Co., Ltd. (300199)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Hybio Pharmaceutical Co., Ltd., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Hybio Pharmaceutical Co., Ltd. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN